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Metformin hydrochloride and sitagliptin phosphate is the
common combination among diabetic drugs. Available dosage
forms cannot avoid the dose dumping which leads to the com-
plication such as lactic acidosis, gastrointestinal complication,
and severe hypoglycemia. Metformin hydrochloride has a very
short half-life, i.e. 4 hrs, and thus fails to give action for the
long period. This leads to the increase number of dosings per
day. Single-unit formulations contain the active ingredient
within the single tablet or capsule,whereasmultiple-unit dosage
forms comprise a number of discrete particles that are com-
bined into one dosage unit. Other advantages of this divided
dose include ease of adjustment of the strength, administra-
tion of incompatible drugs in a single dosage unit by separating
them in different multiparticulates and different drug-release
rates to obtain the desired overall release profile [1].
Metformin has small half-life compared to Sitagliptin phos-
phate; therefore, enteric coated sustained release matrix pellets
were formulated for Metformin to improve the release pattern
while immediate release pellets were formulated for Sitagliptin.
The excipients chosen showed maximum utility even in lesser
quantities, which served their purpose in the formulation of
both types of pellets by extrusion spheronization process.The
process parameters were controlled and the pellets were char-
acterized for Aspect ratio and sphericity. Based on the drug
release studies, batch MET/F/5 was observed to be showing
97.4% of release without coating for 12 hrs and shows less than
10% of drug release in 0.1 N HCl, and thus it was concluded
that enteric coating of sustained release matrix pellets of
Metformin was optimized. Along with this optimized batch of
immediate release sitagliptin phosphate STG/F/8 showed 99.58%
of release within 60 minutes.
The tablets formulated of these immediate release and sus-
tained release pellets are observed to have 95% of content
uniformity. The 8%–10% of coating with Eudragit S 100 and L
100-55 was considered optimum for coating of the pellets.
The scanning electron microscopy of pellets revealed that
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immediate release pellets were with very smooth surface and
sustained release matrix pellets without coating revealed
slightly rough surface. The pellets were compressed in tablets
and the compressed tablets were optimized based on the fri-
ability, hardness and thickness.The tablets were evaluated for
the release pattern and optimized batch showed release of 96.4%
of Sitagliptin in 1 hour while 97.3% of Metformin in 12 hrs.
The developed dosage form of Metformin and Sitagliptin
is expected to control glucose level through controlled release
of drugs.
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Fig. 1 – Immediate and sustained release pellets. (A) Immediate release Sitagliptin phosphate pellets. (B) Sustained release
Metformin hydrochloride pellets.
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